Aplasia in Chronic Phase CML Post-TKI Therapy: A Management Dilemma
Transient cytopenias and bone marrow hypoplasia commonly occur during treatment of CML with TKIs (tyrosine kinase inhibitors). This is usually related to the eradication of CML clones that initially compose the majority of hematopoietic cells in the bone marrow at the time of diagnosis. With continu...
Saved in:
Main Authors: | Jeremy L. Ramdial, Luis E. Aguirre, Robert A. Ali, Ronan Swords, Mark Goodman |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-01-01
|
Series: | Case Reports in Hematology |
Online Access: | http://dx.doi.org/10.1155/2019/4861673 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
CML Developing Three Years after Therapy Completion in a Child with Ph(−) Pre-B-ALL
by: S. Hosseini, et al.
Published: (2011-01-01) -
Cytopenia among CML Patients on Imatinib in Kenya: Types, Grades, and Time Course
by: Angela McLigeyo, et al.
Published: (2020-01-01) -
Condylar Aplasia and Hypoplasia: A Rare Case
by: Peeyush Shivhare, et al.
Published: (2013-01-01) -
Pure White Cell Aplasia and Necrotizing Myositis
by: Peter Geon Kim, et al.
Published: (2016-01-01) -
Rechallenge therapy versus tyrosine kinase inhibitor (TKI) for advanced metastatic colorectal cancer: a retrospective study
by: Chenming Liu, et al.
Published: (2025-02-01)